GSK3640254
Pulmonary Arterial Hypertension
Phase 2Active
Key Facts
About GSK plc
GSK plc is one of the world's leading pharmaceutical companies, headquartered in London, with operations in over 100 countries. The company has transformed from a traditional pharmaceutical giant into a focused biopharma company through strategic divestitures and increased R&D investment. GSK maintains leadership positions in respiratory diseases, HIV treatment, vaccines, and has a growing oncology portfolio. The company is publicly traded on the London Stock Exchange and NYSE with a market capitalization exceeding $100 billion.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| PAH Program | Insmed | Phase 2b |
| Treprostinil (Remodulin) | United Therapeutics | Commercial |
| Treprostinil (Orenitram) | United Therapeutics | Commercial |
| Selexipag (Uptravi) | United Therapeutics | Commercial |
| Ralinepag | United Therapeutics | Phase 3 |
| Orenitram® | Supernus Pharmaceuticals | Approved/Commercial |
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |